The Latest

This Week in HIV Research: From PrEP to Treatment, There's Always More to Learn

April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.

By Barbara Jungwirth and Myles Helfand

Fanconi-Like Lab Abnormalities Reported With Daily PrEP: Importance of Routine Kidney Monitoring

The first case of Fanconi syndrome associated with PrEP was reported in a poster at the 18th International Workshop on Comorbidities and Adverse Drug Reactions in HIV.

By Simon Collins for HIV i-Base

Serious Kidney Problems Are Rare With PrEP, but Increase With Older Age and Better Adherence

Three studies offer reassuring news that adverse kidney changes that accompany Truvada use for PrEP are rarely serious and universally reverse after stopping the medication, but also that older people and those with the best adherence might need to b...

By Project Inform

How PrEP Changes Kidney Function

Research presented at CROI 2016 shows that Truvada PrEP is safe for most people, but impaired kidney function -- usually mild or moderate -- may occur in a small proportion of people on PrEP, especially if they have other risk factors.

By Liz Highleyman for BETA

Truvada as PrEP Does Not Cause Kidney Damage, Study Suggests

Taking Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) has little effect on kidney function, according to a new study.

By Barbara Jungwirth